FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:195-196 July 12, 2007 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Keime-Guibert, F. PubMed Citation

To the Editor: Keime-Guibert et al. (April 12 issue)¹ report a median survival benefit of 12.2 weeks with radiotherapy plus supportive care as compared with supportive care alone for glioblastoma in the elderly. Although this represents an impressive relative survival benefit of approximately 70%, the absolute survival benefit should be placed in context. The median treatment duration was 5.9 weeks. In other words, 48% of the duration of the absolute survival benefit was spent receiving the treatment. The fact that the survival benefit gained is measured in fractions of weeks, not months or years, highlights the limitations of this treatment.

. . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.